The Avid Outdoorsman on MSN
New rifle platform aims to fix long-standing complaints from hunters
Modern hunters have never had more rifle options, yet the same complaints keep surfacing at camp: rifles are too... The post ...
Survival World on MSN
8 common concealed carry mistakes new (and old) gun owners make
One common mistake in concealed carry is neglecting to see your carry gun as part of a comprehensive system. This system ...
We put the top duck hunting ammunition to the test on the range and in the field. Here's how bismuth, steel, and tungsten ...
Wrestling Inc. on MSN
AEW Dynamite & Collision Holiday Bash Results 12/17 - Three Continental Classic Matches And More
This is Wrestling Inc.'s coverage for "AEW Dynamite" and "AEW Collision" Holiday Bash on December 17, 2025, with three ...
AAR Corp.’s AIR robust presence in the aerospace Maintenance, Repair and Overhaul (MRO) market, solid liquidity and low debt are strong positives. Given its growth prospects, AIR makes for a solid ...
Micron Technology, Inc. MU will report first-quarter fiscal 2026 results on Dec. 17, after market close. The company projects fiscal first-quarter revenues to be $12.5 billion (+/- $300 million). The ...
Space Force Capt. Gordon McCulloh was sitting in a military propeller plane high in the calm, dark sky over New Mexico on a recent Wednesday night when his squadron’s group chat blew up. The squadron ...
Shares of Structure Therapeutics surged Monday after the biotechnology company said an experimental pill helped people lose substantial weight in a mid-stage clinical trial. The shares more than ...
Campbell's is a stock for income-oriented value investors to add to their 2026 wish list. Here's why investors are sour on Campbell's, and if the high-yield dividend stock is a buy in December. The ...
Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming patent expirations. Amgen's Q3/25 results showed 12.4% revenue growth, 13.6% ...
Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results